14 completed, 13 recruiting, 8 withdrawn, 6 terminated. 48 Phase 2, 16 Phase 1, 1 Phase 3.
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy High-dose inactivated influenza vaccine, Standard-dose inactivated influenza vaccine - Hematologic Malignancy, Influenza | Phase 2 | Recruiting | Sung-Han Kim | 60 | 2026-11-02 | 2026-11-09 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-06-01 | 2026-06-23 |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant Belumosudil - Graft Versus Host Disease, Graft Vs Host Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2025-05-21 | 2026-06-29 |
| Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial Cold-stored platelet concentrate - Hematologic Malignancy | Phase 2 | Recruiting | Ottawa Hospital Research Institute | 50 | 2025-05-16 | 2025-07-31 |
| CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-12-31 | 2024-12-06 |
| TCR Alpha/Beta and CD19-deplete Haplo-HSCT CliniMACS Plus Instrument - Pediatric Patients, Hematologic Malignancy | Phase 2 | Withdrawn | University of Colorado, Denver | 2024-12-01 | 2024-10-18 | |
| Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI) Posaconazole - Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2024-11-08 | 2026-01-26 |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine - Graft Versus Host Disease, Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 82 | 2024-07-18 | 2026-01-26 |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Shenzhen TargetRx Co., Ltd. | 30 | 2024-03-06 | 2024-04-10 |
| Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010) - Hematologic Malignancy | Phase 2 | Terminated | Prolacta Bioscience | 46 | 2023-09-18 | 2024-08-19 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Fludarabine, Busulfan, Melphalan - Hematologic Malignancy, Acute Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 70 | 2023-05-11 | 2026-04-06 |
| CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 60 | 2023-04-27 | 2025-04-27 |
| Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG) - Hematologic Malignancy, Myeloid Malignancy | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2023-03-14 | 2025-10-02 |
| Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Pirtobrutinib, Venetoclax - Mantle Cell Lymphoma, Non Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-01-25 | 2026-05-05 |
| CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation - Hematologic Diseases, Hematologic Malignancy | Phase 2 | Withdrawn | Baptist Health South Florida | 2022-09-01 | 2022-09-27 | |
| Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome Ruxolitinib - Bronchiolitis Obliterans Syndrome, Hematologic Malignancy | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 50 | 2022-06-01 | 2022-10-19 |
| Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated - B-Cell Lymphoid Malignancies, Hematologic Malignancy | Phase 2 | Withdrawn | Baptist Health South Florida | 2022-03-28 | 2023-11-01 | |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation - Hematologic Malignancy | Phase 1 / Phase 2 | Unknown | Sichuan University | 56 | 2022-03-01 | 2022-03-15 |
| Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) Human T Lymphoid Progenitor (HTLP) injection - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2022-02-16 | 2026-08-12 |
Showing 20 of 48. Sign in to see all of them.
Hematologic Neoplasms (48) · Leukemia, Myeloid, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoma, Non-Hodgkin (5) · Myelodysplastic Syndromes (4) · Myeloproliferative Disorders (4) · Anemia, Aplastic (3) · Anemia, Refractory, with Excess of Blasts (3) · Graft vs Host Disease (3) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (3) · Recurrence (3) · Burkitt Lymphoma (2) · Hodgkin Disease (2)
Hemic and Lymphatic Diseases (48) · Neoplasms (48) · Neoplasms by Site (48) · Hematologic Diseases (47) · Immune System Diseases (14) · Neoplasms by Histologic Type (12) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Bone Marrow Diseases (9) · Disease Attributes (8) · Leukemia, Myeloid (8) · Leukemia (7)
fludarabine (11) · Cyclophosphamide (8) · Whole-Body Irradiation (7) · Busulfan (5) · Melphalan (4) · Tacrolimus (4) · fludarabine phosphate (4) · Antilymphocyte Serum (3) · Methotrexate (3) · Thiotepa (3) · thymoglobulin (3) · Mycophenolic Acid (2) · Radiotherapy (2) · ruxolitinib (2) · tocilizumab (2)
First Affiliated Hospital of Zhejiang University (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Nantes University Hospital (3) · Baptist Health South Florida (2) · Masonic Cancer Center, University of Minnesota (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Abramson Cancer Center at Penn Medicine (1) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Cellphire Therapeutics, Inc. (1) · Chinese PLA General Hospital (1) · Dana-Farber Cancer Institute (1) · Emory University (1)
United States (26) · China (8) · France (5) · Canada (2) · Egypt (1) · Germany (1) · Israel (1) · Italy (1) · Norway (1) · Russia (1) · South Korea (1)
Yi Luo, M.D. (3) · Dolores Grosso, DNP, CRNP (2) · Joanne Kurtzberg, MD (2) · Neal Flomenberg, MD (2) · Alan Tinmouth, MD (1) · Alexandra Gomez Arteaga, MD (1) · Alina Markova, MD (1) · Alisa B Lee Sherick (1) · Anthony Sung, MD (1) · Ashok Srinivasan, MD (1) · Bo Jiang, MD (1) · Claudio Brunstein, MD, PhD (1) · David Porter, MD (1) · Doris Ponce, MD (1)
PMID 31704264, PMID 33022376, PMID 36028757, PMID 36106394, PMID 37467030, PMID 37925363, PMID 38485149, PMID 39293082, PMID 39706761, PMID 42159161
2019 (1), K08HL143189 (1), P30CA008748 (1)